Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 13(1): 5396, 2023 04 03.
Artículo en Inglés | MEDLINE | ID: mdl-37012275

RESUMEN

Toxoplasma gondii (T. gondii) is one of the most successful parasites in the world, because about a third of the world's population is seropositive for toxoplasmosis. Treatment regimens for toxoplasmosis have remained unchanged for the past 20 years, and no new drugs have been introduced to the market recently. This study, performed molecular docking to identify interactions of FDA-approved drugs with essential residues in the active site of proteins of T. gondii Dihydrofolate Reductase (TgDHFR), Prolyl-tRNA Synthetase (TgPRS), and Calcium-Dependent Protein Kinase 1 (TgCDPK1). Each protein was docked with 2100 FDA-approved drugs using AutoDock Vina. Also, the Pharmit software was used to generate pharmacophore models based on the TgDHFR complexed with TRC-2533, TgPRS in complex with halofuginone, and TgCDPK1 in complex with a bumped kinase inhibitor, RM-1-132. Molecular dynamics (MD) simulation was also performed for 100 ns to verify the stability of interaction in drug-protein complexes. Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) analysis evaluated the binding energy of selected complexes. Ezetimibe, Raloxifene, Sulfasalazine, Triamterene, and Zafirlukast drugs against the TgDHFR protein, Cromolyn, Cefexim, and Lactulose drugs against the TgPRS protein, and Pentaprazole, Betamethasone, and Bromocriptine drugs against TgCDPK1 protein showed the best results. These drugs had the lowest energy-based docking scores and also stable interactions based on MD analyses with TgDHFR, TgPRS, and TgCDPK1 drug targets that can be introduced as possible drugs for laboratory investigations to treat T. gondii parasite infection.


Asunto(s)
Toxoplasma , Toxoplasmosis , Humanos , Toxoplasma/genética , Simulación del Acoplamiento Molecular , Toxoplasmosis/tratamiento farmacológico , Tetrahidrofolato Deshidrogenasa/metabolismo
2.
Adv Mater ; 28(32): 6914-20, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27247052

RESUMEN

Gelatin-graphene conductive biopolymer nanocomposites (CPCs) with ultralow percolation threshold are designed by reducing in situ graphene oxide nanosheets with ascorbic acid and suppressing the aggregation of the graphene nanosheets. The resulting conductive nanocomposites show a record-low electrical percolation threshold of 3.3 × 10(-2) vol%, which arises from the homogeneous dispersion of the graphene nanosheets within the gelatin matrix.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...